Assessing the clinical benefits of lipid-disorder drugs

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 396-399

  Hiatt, William R ^a   Smith, Robert J ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; DALCETRAPIB; EZETIMIBE; FENOFIBRATE; ICOSAPENTAENOIC ACID ETHYL ESTER; LAROPIPRANT; NICOTINIC ACID; SIMVASTATIN; TORCETRAPIB;

DRUG APPROVAL; DRUG RESPONSE; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 84893127732     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1313866     Document Type: Article

References (5)

1. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
2. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
3. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369: 1090-8. [Erratum, Lancet 2007;370:220.] (Pubitemid 46483662)
4. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109-22. (Pubitemid 350146106)
5. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.